New book by Larry Connors Click here Improve your trading - See how
To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/xyzal/33941/
"I've lived with indoor and outdoor allergies almost all my life. As a professional golfer, being outside around grass so often and constantly traveling, I know how debilitating the symptoms can be, especially in the fall," says Jill McGill, LPGA golfer and a long-time nasal allergy sufferer. "I take managing my indoor and outdoor allergies very seriously, as my symptoms have made it such that I've almost had to withdraw from tournaments in the past. That is why I am encouraging other nasal allergy sufferers to Challenge their own Course in managing their symptoms."
Challenge Your Course encourages people with indoor and outdoor allergies to visit their physician to review their current allergy management plan. The campaign Web site, www.ChallengeYourCourse.com, offers a variety of helpful information and tools such as an allergy treatment scorecard, tips for managing indoor and outdoor allergies, and additional background on Jill McGill.
"As an allergist, I see how indoor and outdoor allergy symptoms can affect people every day, especially when they are not properly managed," said Beth Corn, MD, assistant professor of medicine at Mount Sinai School of Medicine. "I think it's important for people to realize they can effectively manage their nasal allergies. The first step is to visit a physician to discuss treatment options and determine a program that works best for them so they can enjoy the many fun activities the fall season has to offer."
When speaking with their physician, nasal allergy sufferers can learn about available treatment options, including XYZAL(R) (levocetirizine dihydrochloride), a once-daily prescription medication indicated for the relief of symptoms associated with indoor and outdoor allergies, as well as the treatment of uncomplicated manifestations of chronic idiopathic urticaria (CIU) in adults and children 6 years and older.
Challenge Your Course provides nasal allergy sufferers with the following useful tips, especially helpful during fall allergy season:
-- Keep windows closed to prevent pollen and mold spores from drifting into your home, especially during windy autumn days. Avoid being outside on windy days when pollen counts are higher.
-- Much like mowing the lawn, raking leaves can stir up allergens so avoid this chore if you have severe allergy symptoms.
-- Don't line-dry your clothes outside, as they can collect pollen and mold.
-- When going out to enjoy the fall foliage, avoid the early morning when pollen counts are highest.
-- If you have pets, keep them out of your bedroom to reduce exposure to dander and other allergens they've collected from outside.
Challenge Your Course is supported by UCB and sanofi-aventis, the makers of XYZAL(R) (levocetirizine dihydrochloride).
About XYZAL(R)Indications and Important Safety Information
XYZAL(R) is indicated for the relief of symptoms associated with allergic rhinitis (seasonal and perennial) and the treatment of uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older.
The use of XYZAL(R) is contraindicated in: patients with a known hypersensitivity to levocetirizine or any of the ingredients of XYZAL(R) or to cetirizine (observed reactions range from urticaria to anaphylaxis); patients with end-stage renal impairment at less than 10 mL/min creatinine clearance or patients undergoing hemodialysis; and pediatric patients aged 6 to 11 years with impaired renal function.
Patients should be cautioned against engaging in hazardous occupations requiring complete mental alertness and motor coordination, such as operating machinery or driving a motor vehicle, after ingestion of XYZAL(R). Concurrent use of XYZAL(R) with alcohol or other central nervous system (CNS) depressants should be avoided because additional reductions in alertness and additional impairment of CNS performance may occur.
In clinical trials, the most common adverse reactions in greater than or equal to 2% of adult and adolescent patients (12 years of age and older) taking XYZAL(R) 2.5 mg, XYZAL(R) 5 mg, or placebo were somnolence (5%, 6%, 2%), nasopharyngitis (6%, 4%, 3%), fatigue (1%, 4%, 2%), dry mouth (3%, 2%, 1%), and pharyngitis (2%, 1%, 1%), respectively.
In clinical trials, the most common adverse reactions in greater than or equal to 2% of pediatric patients (6-12 years of age) taking XYZAL(R) 5 mg included pyrexia (4% vs 2% placebo), cough (3% vs greater than or equal to 1% placebo), somnolence (3% vs <1% placebo), and epistaxis (2% vs >1% placebo).
Please visit www.XYZAL.com for full prescribing information.
About Allergic Conditions
Many people suffer from the symptoms associated with common allergic conditions. The immune system of allergy sufferers over-reacts to something in the environment, leading to symptoms that affect their respiratory system, eyes or skin. Experts estimate indoor and outdoor allergies affect as many as 40 million people in the United States.
Seasonal allergic rhinitis (SAR), commonly referred to as "hay fever" or "outdoor allergies," is the most common form of allergic rhinitis. By definition, SAR includes allergies to seasonal pollens like grass, trees, and weeds, as well as mold. Perennial Allergic Rhinitis (PAR) is sometimes referred to as "year round" or "indoor allergies" and is characterized by allergic symptoms that last longer than four weeks. Dust mites, animal dander, and mold most commonly trigger PAR. Chronic Idiopathic Urticaria (CIU) is most commonly known as "chronic hives of unknown origin" and is defined as the occurrence of daily, or almost daily, wheals and itching for at least six weeks with no obvious causes.
About UCB
UCB is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialization of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology. Employing approximately 12,000 people in more than 40 countries, UCB achieved revenue of $4.6 billion (3.5 billion euro) in 2006 on a pro forma basis. UCB is listed on the Euronext Brussels Exchange. Worldwide headquarters is located in Brussels, Belgium; U.S. headquarters is located in Atlanta, Georgia. For more information about UCB, visit www.ucb-group.com.
About sanofi-aventis
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
About AAFA
The Asthma and Allergy Foundation of America (AAFA), www.aafa.org, is the leading non-profit patient organization fighting asthma and allergic diseases. AAFA provides free consumer information, patient education and funding for research to find cures.
SOURCE UCB; sanofi-aventis
http://www.ucb-group.com
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
15260 Ventura Blvd., Ste. 2200
Sherman Oaks, CA 91403
© Copyright 2009 The Connors Group, Inc.
